OBJECTIVES: Allergic rhinitis (AR) affects 20% of the population, and  40% of these patients report a diagnosis of asthma. Previous work has shown that treatment of AR improves asthma control. The objective was to examine healthcare costs related to AR and asthma for patients either treated with MP29-02*, a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate in an advanced delivery system, or combination therapy with single ingredient intranasal antihistamine (INA) and intranasal corticosteroid (INS) sprays METHODS: A retrospective analysis of medical and pharmacy claims of a commercially-insured U.S. population was performed to evaluate differences in costs between two treatment groups (MP29-02* and INA/INS combination therapy).  Medical and pharmacy claims occurring between 9/1/2011-3/31/2014 were used. Inclusion criteria included a diagnosis of rhinitis (defined by ICD-9 472.0, 477.xx), at least 1 claim for a prescription intranasal spray (designated as the index date) during the identification period (9/1/2012—12/31/2013), 12 months pre-index and 6-months post-index continuous enrollment, and no pre-index claims for an intranasal spray. Patients diagnosed with asthma (493.xx) during the observation period were flagged. Inverse propensity score weighting adjustment was used to control for demographic, comorbidity, geographical and seasonal attributes. Adjusted mean AR-related and asthma-related costs for 6-months post-index were compared. RESULTS: Total medical and pharmacy costs for the MP29-02* cohort (n=810) are $2,782, statistically significant lower than for INA/INS cohort (n=726) with $3,493 (P=.0074). For the sub-cohort with asthma, the MP29-02* cohort (n=109) had lower asthma-related pharmacy costs ($247 vs. $796, P=.0193) and lower total asthma-related costs ($565 vs. $1068, P=.0311) compared to the INA/INS asthmatic sub-cohort (n=113).  CONCLUSIONS: For individuals with asthma and rhinitis, MP29-02* is associated with lower asthma-related costs compared to sequential INA/INS therapy in particular for pharmacy costs highlighting the economic impacts of formulation and delivery system in intranasal AR therapy.      *Dymista